Treatment for ischemic stroke
AssigneeCHS Pharma, Inc.
InventorsJang-Yen Wu, Howard Malcolm Prentice
Life of this patent
Estimating the term…
Abstract
Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
Claims7
A method of treating reperfusion injury in the brain of a mammalian subject, the method comprising the step of administering to the subject a N-diethylthiocarbamate sulfoxide (DETC-MeSO) agent, wherein the reperfusion injury is caused by a stroke.
Dependencies are inferred from the claim text.